All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
2 warning events since 2017; the latest 2021-05-03.
From the record
EyePoint, Inc.'s filings since 2017 show 2 warning events of 2 kinds: a notice about its exchange listing (8-K item 3.01, the latest 2020-06-17); a late-report notice (Form NT 10-K or NT 10-Q, the latest 2021-05-03) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+18.3% a year over 10 filed years; profitable in 0 of 10.
From the record
EyePoint, Inc.'s 10 filed years say what it did: revenue went from $8 million in fiscal 2017 to $31 million in fiscal 2025, up 18.3% a year; it rose in 6 of 9 years; the deepest fall was 61% from fiscal 2017 to fiscal 2018; net income was positive in 0 of 10 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 1.7/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: EyePoint, Inc.'s shareholder treatment is put at 1.7 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 17% of 21 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -76%: lost 76¢ per shareholder dollar. Leverage 16%: owes 16¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, EyePoint, Inc. lost about 76 cents for every dollar of shareholders' money. Leverage: it owed about 16 cents per dollar of assets, and net share issuance: its share count grew 30.1% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
bottom 12% of 21 in its family; net margin -739.4%.
From the record
EyePoint, Inc.'s standing among 21 graded names in its industry family: revenue of $31 million in fiscal 2025 ranks in the bottom 26% by size; a net margin of -739.4% ranks in the bottom 7%; revenue growth of -8.8% a year over the last 3 filed years ranks in the bottom 3% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
top 40% of 21 in its family for leadership; chief executive since 2023.
From the record
EyePoint, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Duker, Jay S. (President and CEO, as filed), filing under that title since 2023-07-12, 3.3 years (bottom 39% of its family); the 11 officers and directors filing in the last fifteen months have been on the record a median of 7 years (top 21%); 5 officer or director changes were reported on Form 8-K since 2023-11-13, against the 11 people in charge now (top 39%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
top 37% of 21 in its family for room to expand.
From the record
EyePoint, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $102 million against no long-term debt tagged leaves 28% of its assets as net cash, top 11% of its family; cash from operations less capital spending is -775.8% of revenue (bottom 7%); research spending of 704.6% of revenue (top 7%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
top 49% of 21 in its family for growth drivers.
From the record
EyePoint, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew -8.8% a year over the last three filed years against 18.3% over all 10, slowing (bottom 13% of its family); the newest year grew -27.5% (bottom 2%); research spending grew 64.5% a year (top 2%); capital spending grew 15.1% a year (top 7%) (its annual reports). EyePoint, Inc. reported 3 product lines in fiscal 2025: License and Collaboration Agreement at $17 million (53%), Royalty at $13 million (42%), Product at $2 million (5%); 1 of 3 grew against the year before (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
bottom 8% of 20 in its family for expectations against reality.
From the record
EyePoint, Inc.'s newest year against its own record: revenue of $31 million in fiscal 2025 came in 29.1% below the $44 million its prior three years' pace pointed to (bottom 3% of its family); net income of $232 million against a prior three-year average of $101 million (bottom 18%); a net margin of a loss larger than its revenue against losses larger than its revenue before (bottom 3%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made